Compare Cassava Sciences Inc (FLNA) vs Kaltura Inc (KLTR) Price & Performance

FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.

Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.

Kaltura (KLTR) trades at $1.30, up 2.36% today, showing positive momentum despite a bearish technical signal. The company continues to beat earnings expectations with three consecutive quarterly EPS beats, though it remains unprofitable with a -8.25% net margin. Recent industry recognition includes Frost & Sullivan Global Company of the Year and multiple Gartner leadership positions, highlighting strong competitive positioning in digital experience platforms.

While Kaltura demonstrates improving financial trends with narrowing losses and positive operating cash flow, the stock faces headwinds from persistent unprofitability and high P/B ratio of 42.09. Analyst sentiment is mixed with 44% buy ratings, but technical indicators suggest near-term caution. The company's AI-driven product innovations provide growth catalysts, but execution risk remains elevated.